HBM Wins China IND Nod for Long-Acting Atopic Dermatitis Antibody

HBM Holdings Ltd. ( (HK:2142) ) just unveiled an announcement.

HBM Holdings has reported that China’s National Medical Products Administration has approved the investigational new drug application for HBM7575, also known as SKB575, for the treatment of atopic dermatitis. The candidate is a long-acting bispecific antibody that targets thymic stromal lymphopoietin and a second undisclosed antigen, designed with dual mechanisms to improve efficacy and overcome resistance seen with single-target TSLP antibodies.

The therapy has been engineered for extended half-life and subcutaneous dosing, with preclinical data suggesting dosing intervals of more than three months, potentially positioning it as a best-in-class option. Under its collaboration with Sichuan Kelun-Biotech Biopharmaceutical, Kelun-Biotech will lead global design, development and commercialization of HBM7575, while HBM participates in investment and shares future economic benefits, reinforcing its strategy of leveraging partnerships to advance its pipeline.

The most recent analyst rating on (HK:2142) stock is a Hold with a HK$11.50 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.

More about HBM Holdings Ltd.

HBM Holdings Limited is a Cayman Islands-incorporated biopharmaceutical company listed in Hong Kong, focused on developing innovative antibody therapies. The group advances differentiated biologics through in-house R&D and partnerships, targeting immune-related diseases and other areas with high unmet medical need in China and global markets.

Average Trading Volume: 3,859,038

Technical Sentiment Signal: Buy

Current Market Cap: HK$10.67B

Learn more about 2142 stock on TipRanks’ Stock Analysis page.